TABLE 2.
Perceived barriers to pharmacogenetic tests use.
| Ever used pharmacogenetic tests | Total | p-value | |||||
|---|---|---|---|---|---|---|---|
| No N = 103 83.7% | Yes N = 20 16.3% | ||||||
| N | % | N | % | N | % | ||
| What are the main barriers to the use of pharmacogenetic tests? (% yes) | |||||||
| Provider-related barriers *** | 91 | 88.4 | 13 | 65 | 104 | 84.6 | 0.00 |
| Lack of personal knowledge about pharmacogenetics | 56 | 54.4 | 7 | 35 | 63 | 51.2 | 0.11 |
| Not knowing where they are available ** | 51 | 49.5 | 4 | 20 | 55 | 44.7 | 0.02 |
| Not knowing how to request them ** | 38 | 36.9 | 2 | 10 | 40 | 32.5 | 0.02 |
| Complexity to request tests | 13 | 12.6 | 2 | 10 | 15 | 12.2 | 0.74 |
| Complexity to interpret the results ** | 7 | 6.8 | 5 | 25 | 12 | 9.8 | 0.01 |
| Healthcare system-related barriers | 81 | 78.6 | 18 | 90 | 99 | 80.5 | 0.24 |
| High cost of available tests ** | 46 | 44.7 | 14 | 70 | 60 | 48.8 | 0.04 |
| Lack of availability of pharmacogenetic tests in Chile | 49 | 47.6 | 8 | 40 | 57 | 46.3 | 0.53 |
| Lack of coverage by health systems | 41 | 39.8 | 11 | 55 | 52 | 42.3 | 0.2 |
| Lack of evidence of clinical utility *** | 26 | 25.2 | 11 | 55 | 37 | 30.1 | 0.00 |
| Other | 5 | 4.9 | 0 | 0 | 5 | 4.1 | 0.31 |
| Will incorporate the use of pharmacogenetic tests in its clinical practice in the next 5 years | |||||||
| Yes | 73 | 80.2 | 14 | 77.8 | 87 | 79.8 | 0.81 |
*** p < 0.01, ** p < 0.05, * p < 0.1.